Current label answer
The 6% to 8% figures cover a group of local reactions
The current Eli Lilly Zepbound prescribing information was updated April 22, 2026. In two pooled placebo-controlled adult weight-reduction trials, injection-site reactions were reported in 6%, 8%, and 8% of patients receiving 5 mg, 10 mg, and 15 mg, respectively, compared with 2% receiving placebo. The grouped category included injection-site bruising, redness, itching, pain, rash, and unspecified reaction. It does not provide a separate rate for any one appearance, establish one expected onset or duration, or predict what will happen to an individual patient.
- Keep 6%, 8%, 8%, and 2% tied to the pooled adult Zepbound weight-reduction trials and the grouped label term.
- Do not describe 6% to 8% as a redness-only, itching-only, rash-only, pain-only, bruise-only, lump, swelling, or burning rate.
- A trial association cannot diagnose irritation, allergy, infection, bleeding, tissue injury, or another cause in one person.
Product identity
Zepbound, Mounjaro, and compounded tirzepatide are different finished products
Zepbound is an FDA-approved Eli Lilly tirzepatide injection with product-specific weight-management and obstructive-sleep-apnea labeling. Current labeling includes single-dose pens and vials, multi-dose vials, and single-patient-use KwikPens. Mounjaro also contains tirzepatide but has different branded labeling, indication context, presentations, and trial-specific reaction data. A patient-specific compounded tirzepatide preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, container, supplies, storage instructions, and beyond-use date.
- Confirm the brand or pharmacy label, active ingredient, route, presentation, prescriber, dispensing pharmacy, refill or lot information, and storage history.
- Do not transfer Zepbound trial percentages to Mounjaro, a compounded prescription, a research-use vial, or a product with uncertain identity.
- Avoid “generic Zepbound,” no-prescription pens, unlabeled mixtures, loose powder, copied syringe conversions, and sellers that cannot identify a licensed prescriber and legitimate dispensing pharmacy.
Local versus whole-body symptoms
A local mark and a serious allergic reaction are different safety questions
A red, itchy, firm, sore, bruised, or swollen area near an injection does not automatically prove a serious medication allergy. However, current Zepbound labeling reports serious hypersensitivity reactions, including anaphylaxis and angioedema. Facial, lip, tongue, or throat swelling; trouble breathing or swallowing; wheezing; widespread hives; fainting; severe confusion; or a rapidly developing whole-body reaction can require emergency care. A photo, percentage, or online symptom checklist cannot rule out serious allergy.
- Call emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, or a rapidly worsening widespread reaction.
- Do not use another injection as a test or start an unreviewed antihistamine, steroid, or other medicine simply to stay on schedule.
- Tell the care team about prior medication allergy, anaphylaxis, angioedema, eczema, adhesive reactions, and every new medicine, supplement, or topical exposure.
Trend and local warning signs
Border, warmth, pain, drainage, and fever matter more than one snapshot
Useful details include how soon the reaction appeared, its approximate size and location, whether its border is stable or expanding, and whether redness, itching, warmth, pain, firmness, swelling, bruising, drainage, red streaks, fever, blistering, darkening, numbness, or skin breakdown is present. Rapid spread, increasing warmth or pain, pus, streaking, fever, or feeling acutely unwell can require prompt in-person assessment for infection or another complication. Severe or disproportionate pain, color change, blistering, numbness, or skin breakdown also should not be managed through a seller chat or forum.
- Use dated photos with a size reference only when the care team requests them; lighting and skin tone can make color alone misleading.
- Seek prompt local assessment for rapid spread, severe or escalating pain, pus, red streaks, fever or chills, blistering, darkening, numbness, or skin breakdown.
- Contact the prescriber for a reaction that persists, returns after injections, enlarges, worsens, becomes unusually painful, or limits treatment even when emergency features are absent.
Site and package review
Use unaffected skin and the instructions for the exact Zepbound presentation
The current Zepbound label lists the abdomen, thigh, or back of the upper arm and directs site rotation; another person should inject in the upper arm. General MedlinePlus subcutaneous-injection guidance says not to use an area with redness, swelling, scarring, bruising, or other skin or tissue damage. These points support avoiding an affected area and asking for presentation-specific guidance. They do not justify an improvised pen or vial step, a repeated dose, a copied injection diagram, or a universal home-treatment plan.
- Report whether the skin was already red, swollen, bruised, scarred, hardened, irritated, recently shaved, or affected by eczema, infection, or another condition.
- Note any new cleanser, alcohol prep, adhesive, bandage, lotion, topical medicine, clothing friction, caregiver help, or pre-existing skin problem near the site.
- Ask the prescriber, pharmacist, or manufacturer support team to review unclear package, pen, vial, KwikPen, storage, or site-rotation questions before another treatment decision.
Antibody evidence
A group-level antibody association cannot explain one reaction
In the pooled Zepbound weight-reduction trials, the label reports injection-site reactions more often among treated patients who developed anti-tirzepatide antibodies than among treated patients who did not develop them: 11.3% versus 1%. This is an association from trial groups, not a home test, a diagnosis, or proof that antibodies caused one person’s reaction. It should not be used to predict treatment effectiveness, justify unvalidated testing, or direct a dose or product change without the responsible clinician.
- Do not order or interpret unvalidated antibody testing from an online seller to explain a local mark.
- Do not assume that a reaction means Zepbound has stopped working or that the dose should be changed, repeated, or replaced.
- Ask the responsible clinician whether recurrence, severity, whole-body symptoms, or treatment impact changes the monitoring or next-step plan.